Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
It is expanding the diagnostics business footprint in North East India
The plant is expected to start commercial operations from Q4FY24
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Subscribe To Our Newsletter & Stay Updated
